[artículo] 
inJournal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 1 (Febrero) . - pp. 28-34

Título :	Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder
Tipo de documento:	texto impreso
Autores:	Marcio Versiani, Autor ; Mohammed Amin, Autor ; Guy Chouinard, Autor
Fecha de publicación:	2023
Artículo en la página:	pp. 28-34
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Antidepresivos, Trastorno depresivo mayor, Morfolinas.
Resumen:	The efficacy and tolerability of reboxetine, a unique selective noradrenaline reuptake inhibitor, were compared with those of placebo in a 6-week, randomized, double-blind study of hospitalized patients with a DSM-III-R diagnosis of major depressive disorder. Fifty-two patients (25 in the placebo group, 27 in the reboxetine group) were included in the efficacy analysis.
Link:	./index.php?lvl=notice_display&id=31228

[artículo] Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder [texto impreso] / Marcio Versiani, Autor ; Mohammed Amin, Autor ; Guy Chouinard, Autor . - 2023 . - pp. 28-34.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 1 (Febrero) . - pp. 28-34

Palabras clave:	Antidepresivos, Trastorno depresivo mayor, Morfolinas.
Resumen:	The efficacy and tolerability of reboxetine, a unique selective noradrenaline reuptake inhibitor, were compared with those of placebo in a 6-week, randomized, double-blind study of hospitalized patients with a DSM-III-R diagnosis of major depressive disorder. Fifty-two patients (25 in the placebo group, 27 in the reboxetine group) were included in the efficacy analysis.
Link:	./index.php?lvl=notice_display&id=31228